Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker OGN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to… NCT07265479 · Atopic Dermatitis Tapinarof cream, 1%, Vehicle Cream | OGN Organon and Co | Phase 3 | Active, not recruiting was suspended | 187 | Aug 2027 | Registry ↗ |
| Nov 5, 2026 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects NCT05172726 · Plaque Psoriasis tapinarof cream, 1% | OGN Organon and Co | Phase 3 | Completed was active, not recruiting | 58 | Oct 14, 2026 | Registry ↗ |
| May 8, 2026 | A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in… NCT05560646 · Endometriosis OG-6219, Placebo | OGN Organon and Co | Phase 2 | Completed | 354 | May 28, 2025 | Registry ↗ |
| Apr 8, 2026 | An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Eto… NCT00967746 · Contraception Etonogestrel-releasing IUS, Etonogestrel-releasing IUS | OGN Organon and Co | Phase 2 | Completed | 84 | Nov 2010 | Registry ↗ |
| Apr 8, 2026 | A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With… NCT00651807 · Benign Prostatic Hyperplasia (BPH) etonogestrel, Placebo | OGN Organon and Co | Phase 2 | Terminated | 16 | Aug 2008 | Registry ↗ |
| Feb 18, 2026 | A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of… NCT04626596 · Contraception Radiopaque Etonogestrel (ENG) Implant | OGN Organon and Co | Phase 3 | Completed | 498 | Dec 30, 2024 | Registry ↗ |
| Nov 21, 2025 | Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive NCT05264506 · Contraception NOMAC-E2 COC | OGN Organon and Co | Phase 3 | Terminated | 3,055 | Jan 12, 2024 | Registry ↗ |
| Sep 9, 2025 | Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Pat… NCT05761444 · Atherosclerotic Cardiovascular Disease Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg | OGN Organon and Co | Phase 4 | Completed | 137 | Sep 4, 2024 | Registry ↗ |
| Sep 5, 2025 | Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis NCT05186805 · Atopic Dermatitis Tapinarof cream, 1% | OGN Organon and Co | Phase 2 | Completed | 36 | Aug 24, 2022 | Registry ↗ |
| Sep 4, 2025 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults NCT05014568 · Atopic Dermatitis tapinarof cream, 1%, Vehicle cream | OGN Organon and Co | Phase 3 | Completed | 407 | Mar 30, 2023 | Registry ↗ |
| Sep 2, 2025 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) NCT05032859 · Atopic Dermatitis tapinarof cream, 1%, vehicle cream | OGN Organon and Co | Phase 3 | Completed | 406 | Feb 3, 2023 | Registry ↗ |
| Aug 13, 2025 | Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis NCT05142774 · Atopic Dermatitis Tapinarof cream, 1% | OGN Organon and Co | Phase 3 | Completed | 728 | Feb 29, 2024 | Registry ↗ |
| Aug 6, 2025 | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) NCT04053387 · Plaque Psoriasis tapinarof cream, 1% | OGN Organon and Co | Phase 3 | Completed | 763 | Apr 6, 2021 | Registry ↗ |
| Jun 19, 2025 | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis NCT04042103 · Plaque Psoriasis Tapinarof cream, 1% | OGN Organon and Co | Phase 2 | Completed | 21 | Jan 9, 2020 | Registry ↗ |
| Jun 12, 2025 | A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in t… NCT05789576 · Psoriasis VTAMA (tapinarof) cream, 1% | OGN Organon and Co | Phase 4 | Completed | 31 | Jun 30, 2023 | Registry ↗ |
| Jun 12, 2025 | A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque… NCT05680740 · Psoriasis VTAMA® (tapinarof) Cream 1% | OGN Organon and Co | Phase 4 | Completed | 34 | May 18, 2023 | Registry ↗ |
| Jun 12, 2025 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) NCT03983980 · Plaque Psoriasis Tapinarof, Vehicle Cream | OGN Organon and Co | Phase 3 | Completed | 515 | May 13, 2020 | Registry ↗ |
| Jun 12, 2025 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) NCT03956355 · Plaque Psoriasis Tapinarof, Vehicle Cream | OGN Organon and Co | Phase 3 | Completed | 510 | May 26, 2020 | Registry ↗ |
| Jun 4, 2025 | A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis NCT02094235 · Atopic Dermatitis E6005 0.05%, Placebo | OGN Organon and Co | Phase 1/2 | Completed | 62 | Dec 2014 | Registry ↗ |
| Jun 4, 2025 | A Study of E6005 in Japanese Patients With Atopic Dermatitis NCT01179880 · Atopic Dermatitis E6005, Placebo | OGN Organon and Co | Phase 1/2 | Completed | 40 | Dec 2012 | Registry ↗ |
| Jun 3, 2025 | A Phase 2 Study of E6005 in Patients With Atopic Dermatitis NCT01461941 · Atopic Dermatitis E6005, E6005 ointment (vehicle) | OGN Organon and Co | Phase 2 | Completed | 78 | Nov 2012 | Registry ↗ |
| Sep 19, 2024 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P0571… NCT00703014 · Pregnancy, Neonates Corifollitropin Alfa 150 μg, 200 IU RecFSH/Follitropin beta… | OGN Organon and Co | — | Completed | 541 | Apr 18, 2008 | Registry ↗ |
| Sep 5, 2024 | A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204) NCT01414192 · Dyslipidemia, Hypercholesterolemia | OGN Organon and Co | — | Completed | 3,215 | Sep 15, 2014 | Registry ↗ |
| Sep 5, 2024 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783) NCT00702520 · Pregnancy, Neonates Corifollitropin alpha (MK-8962, Org 36286) 100 ug, Corifoll… | OGN Organon and Co | — | Completed | 15 | Nov 7, 2007 | Registry ↗ |
| Sep 5, 2024 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P0571… NCT00702338 · Pregnancy, Neonates corifollitropin alfa, recombinant Follicle Stimulating Horm… | OGN Organon and Co | — | Completed | 1 | Aug 9, 2008 | Registry ↗ |
| Sep 5, 2024 | Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in… NCT00702273 · In Vitro Fertilization 150 µg Corifollitropin Alfa, 200 IU RecFSH/Follitropin beta… | OGN Organon and Co | — | Completed | 344 | May 19, 2009 | Registry ↗ |
| Sep 5, 2024 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care… NCT00702234 · Pregnancy, Neonates Corifollitropin alfa, GnRH antagonist | OGN Organon and Co | — | Completed | 268 | Oct 22, 2009 | Registry ↗ |
| Sep 5, 2024 | Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant… NCT00070707 · Rhinitis, Allergic, Seasonal, Asthma Mometasone, Placebo | OGN Organon and Co | Phase 4 | Completed | 188 | Nov 26, 2003 | Registry ↗ |
| Sep 4, 2024 | A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With A… NCT01673620 · Allergic Rhinitis Montelukast 10 mg/loratadine 10 mg, Placebo | OGN Organon and Co | Phase 3 | Completed | 69 | Oct 10, 2012 | Registry ↗ |
| Aug 29, 2024 | Survey of Osteoarthritis Real World Therapies (MK-0663-140) NCT01294696 · Osteoarthritis Standard of care for treatment of osteoarthritis (OA) of kn… | OGN Organon and Co | — | Completed | 1,261 | Jan 2013 | Registry ↗ |
| Aug 23, 2024 | A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038) NCT00092651 · Hypercholesterolemia MK0653A, ezetimibe (+) simvastatin, Comparators: simvastati… | OGN Organon and Co | Phase 3 | Completed | 1,398 | Jun 2003 | Registry ↗ |
| Aug 15, 2024 | Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED) NCT00988260 · Controlled Ovarian Stimulation Ganirelix, Ganirelix | OGN Organon and Co | Phase 2 | Completed | 266 | Apr 12, 2004 | Registry ↗ |
| Aug 15, 2024 | An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patien… NCT00878462 · Psychosis Asenapine WHITE raspberry flavor (Treatment A), Asenapine R… | OGN Organon and Co | Phase 2 | Completed | 174 | Oct 15, 2005 | Registry ↗ |
| Aug 15, 2024 | Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Sub… NCT00867191 · Seasonal Allergic Rhinitis Placebo, Desloratadine | OGN Organon and Co | Phase 4 | Completed | 233 | Apr 1, 2003 | Registry ↗ |
| Aug 15, 2024 | A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Stu… NCT00835094 · Asthma Mometasone furoate, Mometasone furoate | OGN Organon and Co | Phase 4 | Completed | 216 | Jul 1, 2003 | Registry ↗ |
| Aug 15, 2024 | Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Or… NCT00834119 · Rhinitis, Allergic Mometasone furoate, Mometasone furoate | OGN Organon and Co | Phase 4 | Completed | 72 | Apr 1, 2004 | Registry ↗ |
| Aug 15, 2024 | A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment… NCT00817817 · Asthma MF, MF | OGN Organon and Co | Phase 3 | Completed | 93 | May 1, 2003 | Registry ↗ |
| Aug 15, 2024 | Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented… NCT00817050 · Allergic Rhinitis Mometasone Furoate Nasal Spray, fluticasone nasal spray | OGN Organon and Co | Phase 4 | Completed | 100 | Jan 1, 2005 | Registry ↗ |
| Aug 15, 2024 | The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609) NCT00789152 · Allergic Rhinitis desloratadine, levocetirizine | OGN Organon and Co | Phase 3 | Completed | 81 | May 1, 2004 | Registry ↗ |
| Aug 15, 2024 | Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented… NCT00783458 · Allergic Rhinitis Mometasone Furoate Nasal Spray, fluticasone nasal spray | OGN Organon and Co | Phase 4 | Completed | 100 | Jan 1, 2005 | Registry ↗ |
| Aug 15, 2024 | A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Stu… NCT00783354 · Urticaria, Chronic Idiopathic Urticaria desloratadine, desloratadine | OGN Organon and Co | Phase 4 | Completed | 129 | Feb 1, 2004 | Registry ↗ |
| Aug 15, 2024 | Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431) NCT00783237 · Allergic Rhinitis Mometasone, Placebo | OGN Organon and Co | Phase 4 | Completed | 340 | Feb 21, 2004 | Registry ↗ |
| Aug 15, 2024 | Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal All… NCT00783211 · Seasonal Allergic Rhinitis desloratadine, fexofenadine | OGN Organon and Co | Phase 4 | Completed | 722 | Oct 1, 2004 | Registry ↗ |
| Aug 15, 2024 | Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal All… NCT00783146 · Seasonal Allergic Rhinitis desloratadine, fexofenadine | OGN Organon and Co | Phase 4 | Completed | 728 | Oct 1, 2004 | Registry ↗ |
| Aug 15, 2024 | Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P031… NCT00783133 · Seasonal Allergic Rhinitis Desloratadine 5 mg, fexofenadine | OGN Organon and Co | Phase 4 | Completed | 131 | Jun 1, 2003 | Registry ↗ |
| Aug 15, 2024 | Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419) NCT00779740 · Rhinitis, Allergic, Perennial mometasone furoate, mometasone furoate | OGN Organon and Co | Phase 3 | Completed | 102 | Apr 1, 2005 | Registry ↗ |
| Aug 15, 2024 | Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Polle… NCT00779636 · Allergic Airway Disease Desloratadine, Placebo | OGN Organon and Co | Phase 4 | Completed | 506 | Nov 1, 2004 | Registry ↗ |
| Aug 15, 2024 | A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED) NCT00779545 · Rhinitis, Allergic, Perennial Placebo, Mometasone furoate | OGN Organon and Co | Phase 2 | Completed | 455 | Aug 6, 2004 | Registry ↗ |
| Aug 15, 2024 | MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED) NCT00771160 · Rhinitis, Allergic montelukast sodium | OGN Organon and Co | Phase 3 | Completed | 120 | Feb 2005 | Registry ↗ |
| Aug 15, 2024 | Elocon vs Fluticasone in Localized Psoriasis (P03197) NCT00763529 · Psoriasis Mometasone, Fluticasone | OGN Organon and Co | Phase 4 | Completed | 245 | Jan 1, 2005 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances